Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters








Language
Year range
1.
IBJ-Iranian Biomedical Journal. 2017; 21 (4): 270-274
in English | IMEMR | ID: emr-189236

ABSTRACT

Background: Reduction/alkylation is one of the leading strategies for the development of antibody drug conjugates [ADCs]. Precise control of the reduction process would not only yield a defined number of free thiols per antibody but also result in development of more homogenous conjugates


Methods: In the present study, we investigated the effect of various dithiothreitol [DTT] concentrations, temperature conditions, and DTT exposure times on antibody reduction. After antibody reduction, the Ellman's test and SDS-PAGE analysis were used to evaluate free thiols produced and confirm the reduction process, respectively


Results: DTT concentration seems to be a potential factor in the reduction process. Concentrations of 0.1, 1, 5, 10, 20, 50, and 100 mM DTT at 37[degree]C for 30 minutes resulted in approximately 0.4, 1.2, 5.4, 7, 8, 8, and 8 thiols per antibody, respectively


Conclusion: Optimized site specific conjugation can provide better process control and reproducibility for the development of disulfide-based ADCs


Subject(s)
Oxidation-Reduction , Pharmaceutical Preparations , Trastuzumab , Temperature , Sulfhydryl Compounds , Alkylation , Electrophoresis, Polyacrylamide Gel , Dithiothreitol
2.
Novelty in Biomedicine. 2017; 5 (4): 145-151
in English | IMEMR | ID: emr-189664

ABSTRACT

Background: Monomethyl auristatin E [MMAE] is a synthetic analog of dolastatin 10, a compound originally isolated from the marine mollusk. MMAE, as a highly potent microtubule inhibitor, exerts its potent cytotoxic effect by inhibiting microtubule assembly, tubulin-dependent GTP hydrolysis and microtubes polymerization. This molecule, by itself, lacks the tumor specificity required to elicit therapeutic benefit. Nevertheless, the extremely cytotoxic potential of MMAE could be harnessed in the form of MMAE-antibody conjugates. The aim of the present study was to evaluate the cytotoxic activity of MMAE against breast [SKBR3] and kidney [HEK293] cancer cell lines in an in vitro cell-based assay


Materials and Methods: SKBR3 and HEK293 cells were treated with different concentrations ranging from 0.002048, 0.01024, 0.0512, 0.256, 1.28, 6.4, 32, 160, 800 and 4000 nM of MMAE, and cell viability was determined after 72 hours using an MTT colorimetric assay. The effect of MMAE was regularly monitored by direct observation using an invert microscope


Results: Microscopic observation showed that there was a concentration-dependent increase in cell death


Results from the MTT assay revealed a statistically significant loss of viability [P<0.0001] at concentrations ranging from 0.01024 to 4000 nM in SKBR3 cells, and 0.0512 to 4000 nM in HEK293 cells. Our findings showed that MMAE inhibited the growth of SKBR3 and HEK293 cells in a concentration-dependent manner, with IC50 values of 3.27 +/- 0.42 and 4.24 +/- 0.37 nM, respectively


Conclusion: MMAE was able to significantly inhibit cell growth at nanomolar concentrations, emphasizing its great potential for the development of antibody-drug conjugates


Subject(s)
HEK293 Cells , Cell Line, Tumor , In Vitro Techniques , Kidney Neoplasms , Oligopeptides
SELECTION OF CITATIONS
SEARCH DETAIL